TSXV:BTI.H - Post by User
Comment by
JDavenporton Apr 23, 2022 12:10pm
170 Views
Post# 34626246
RE:XB3 and its cost in the health care system?
RE:XB3 and its cost in the health care system? My understanding, narmac, is that the manufacturing of a drug like xB3-001 using a genetically programmed cell line to produce fusion proteins, is not that much different than producing the Herceptin monoclonal antibody (mAb) without xB3. In a fusion protein, the xB3-Payload combination are produced in a unit by the cell line and that's why they're called
fusion proteins.
It's probably a long shot speculation but it would be interesting if Protalix is working on producing xB3-001 using their ProCellEx technology. Using plant cells to manufacture mAbs is considerably less expensive than using the tightly-controlled environments and sophisticated equipment of using mammalian cell lines as WuXi does.
And then there is the commercial return of drugs like xB3-001 that can mitigate all costs of production. Big money...
jd